California State Teachers Retirement System Lowers Position in Progress Software Co. (PRGS)


California State Teachers Retirement System Lowers Position in Progress Software Co. (PRGS)

This represents a $0.56 dividend on an annualized basis and a yield of 1.11%. It fall, as 47 investors sold EBAY shares while 306 reduced holdings. 37 funds opened positions while 61 raised stakes. Everence Cap Mngmt stated it has 0.11% of its portfolio in eBay Inc. (NASDAQ:EBAY). Cohen Klingenstein Lc stated it has 9,200 shares or 0.05% of all its holdings. Ubs Asset Mgmt Americas Inc owns 0% invested in Progress Software Corporation (NASDAQ:PRGS) for 25,619 shares. (NASDAQ:EPZM). State Street Corp has invested 0% in Epizyme, Inc. "(NASDAQ:PRGS)" was first posted by StockNewsTimes and is owned by of StockNewsTimes. (NYSE:BWA). Farmers Merchants Investments holds 70 shares. Fmr Lc reported 0.02% of its portfolio in Epizyme, Inc.

Progress Software (NASDAQ:PRGS) opened at $50.55 on Friday. Deutsche Bank & Trust Ag has 76,730 shares. Baker Bros Advisors Limited Partnership owns 232,481 shares for 0.04% of their portfolio. Bluecrest Management Ltd has 0.01% invested in Epizyme, Inc. About 15.38 million shares traded or 18.94% up from the average. Regions Financial Corporation accumulated 31,209 shares.

Currently, the 14-day ADX for Progress Software (PRGS) is sitting at 24.64. Price T Rowe Assocs Md reported 1.79M shares.

I-65 south remains closed near Seymour due to fiery crash
According to police, one of the trucks was carrying four different types of hazardous materials that spilled and mixed . One person, a passenger in one of the semis, was transported to the hospital with non-life threatening injuries.

Since August 24, 2017, it had 1 insider purchase, and 3 sales for $2.32 million activity. $2.61M worth of eBay Inc. (NASDAQ:EPZM) or 200,000 shares.

Analysts await Progress Software Corporation (NASDAQ:PRGS) to report earnings on January, 15.

Among 22 analysts covering Charles Schwab (NYSE:SCHW), 15 have Buy rating, 0 Sell and 7 Hold. Therefore 92% are positive. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. In the most recent quarterly financial report, for the quarter ending November 2017, Progress Software Corporation (PRGS) delivered a 1.75% surprise with its net revenue. Of those analysts, 1 rate stock as a Strong Buy, 2 rate it as Hold, and just no analyst rates it as a Moderate Sell. The stock has "Buy" rating by Benchmark on Friday, January 15. The company was maintained on Friday, October 2 by Wedbush. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued. The rating was maintained by Wedbush on Wednesday, January 18 with "Neutral". The stock of Epizyme, Inc. Maxim Group maintained the stock with "Buy" rating in Thursday, July 13 report. The firm has "Buy" rating given on Tuesday, April 5 by Citigroup. This indicates more upside for the $2.45 billion company. Secor Advsrs Lp stated it has 0.13% in Epizyme, Inc. The rating was maintained by Wedbush with "Neutral" on Wednesday, January 18. The stock was trading at a distance of -2.78% from its 52-week highs and stands 53.12% away from its 52-week lows. About 270,998 shares traded. It has outperformed by 8.30% the S&P500. (NYSE:BWA) to report earnings on February, 8. The Sadoff Investment Management Llc holds 917,195 shares with $40.12M value, up from 907,395 last quarter. The software maker reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.54 by $0.13.

United States hospital caught dumping half-naked mentally ill patient on the road?
The security staff of University of Maryland Medical Centre in Baltimore were recorded dumping a patient near the bus stop. The woman appears to have a wound on her forehead and can be heard mumbling or screaming at times.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has its outstanding shares of 1.67B. The Company's product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It now has negative earnings.

More news for Epizyme, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

MP denuncia policial que atirou em Emily por homicídio qualificado
A família alegou que não parou o veículo porque o bebê estava no banco da frente do veículo com a mãe. Entre os possíveis crimes imputados aos policiais estão homicídio e fraude processual.

Últimas notícias